Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.2 AUD | +0.80% | +1.95% | -5.00% |
Apr. 29 | Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% | MT |
Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.00% | 505M | |
-0.07% | 91.42B | |
+2.76% | 41.08B | |
-9.06% | 34.26B | |
+55.32% | 25.27B | |
-16.61% | 15.27B | |
-9.14% | 12.81B | |
-12.11% | 11.6B | |
-43.61% | 11.42B | |
+7.79% | 9.16B |
- Stock Market
- Equities
- CUV Stock
- News Clinuvel Pharmaceuticals Limited
- Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%